Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Maria Karlgren & Magnus Ingelman-Sundberg. (2007) Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opinion on Therapeutic Targets 11:1, pages 61-67.
Read now
Read now
William A. Denny. (2004) Tumor-activated Prodrugs—A New Approach to Cancer Therapy. Cancer Investigation 22:4, pages 604-619.
Read now
Read now
On Kan, Susan Kingsman & Stuart Naylor. (2002) Cytochrome P450-based cancer gene therapy: current status. Expert Opinion on Biological Therapy 2:8, pages 857-868.
Read now
Read now
Articles from other publishers (39)
Zhihao Wen, Yuxiao Zhang, Xiangyao Wang, Yaxin Wu, Jing Mao, Qilin Li & Shiqiang Gong. (2023) THBS1-Mediated Degradation of Collagen via the PI3K/AKT Pathway Facilitates the Metastasis and Poor Prognosis of OSCC. International Journal of Molecular Sciences 24:17, pages 13312.
Crossref
Crossref
Ragini D. SinghAvadhesh AvadheshGaurav SharmaSagar DholariyaRima B. ShahBela GoyalSubash Chandra Gupta. (2023) Potential of Cytochrome P450, a Family of Xenobiotic Metabolizing Enzymes, in Cancer Therapy. Antioxidants & Redox Signaling 38:10-12, pages 853-876.
Crossref
Crossref
Hannah J. Vaughan & Jordan J. Green. (2021) Recent advances in gene therapy for cancer theranostics. Current Opinion in Biomedical Engineering 20, pages 100300.
Crossref
Crossref
Bei Wang, Lujin Wu, Jing Chen, Lingli Dong, Chen Chen, Zheng Wen, Jiong Hu, Ingrid Fleming & Dao Wen Wang. (2021) Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Jishi Wang, Dan Ma, Yan Li, Yuan Yang, Xiaoyan Hu, Wei Zhang & Qin Fang. (2014) Targeted delivery of CYP2E1 recombinant adenovirus to malignant melanoma by bone marrow-derived mesenchymal stem cells as vehicles. Anti-Cancer Drugs 25:3, pages 303-314.
Crossref
Crossref
Zahra Karjoo, Vidya Ganapathy & Arash Hatefi. 2014. Gene Therapy of Cancer. Gene Therapy of Cancer
77
91
.
Yanhui Yang, Yu Chen, Herve Aloysius, Daigo Inoyama & Longqin Hu. 2013. Enzyme Technologies. Enzyme Technologies
163
235
.
Paul R Ortiz de Montellano. (2013) Cytochrome P450-activated prodrugs. Future Medicinal Chemistry 5:2, pages 213-228.
Crossref
Crossref
Jan Brezovsky, Eva Chovancova, Artur Gora, Antonin Pavelka, Lada Biedermannova & Jiri Damborsky. (2013) Software tools for identification, visualization and analysis of protein tunnels and channels. Biotechnology Advances 31:1, pages 38-49.
Crossref
Crossref
Chien-Fu Hung, An Jen Chiang, Hsiao-Hsuan Tsai, Martin G. Pomper, Tae Heung Kang, Richard R. Roden & T.-C. Wu. (2012) Ovarian Cancer Gene Therapy Using HPV-16 Pseudovirion Carrying the HSV-tk Gene. PLoS ONE 7:7, pages e40983.
Crossref
Crossref
Dipak Panigrahy, Emily R. Greene, Ambra Pozzi, Dao Wen Wang & Darryl C. Zeldin. (2011) EET signaling in cancer. Cancer and Metastasis Reviews 30:3-4, pages 525-540.
Crossref
Crossref
Dipak Panigrahy, Arja Kaipainen, Emily R. Greene & Sui Huang. (2010) Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer and Metastasis Reviews 29:4, pages 723-735.
Crossref
Crossref
William E. Blanco-Bose, Mark J. Murphy, Armin Ehninger, Sandra Offner, Christelle Dubey, Wendong Huang, David D. Moore & Andreas Trumpp. (2008) C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology 48:4, pages 1302-1311.
Crossref
Crossref
Thien-An Nguyen, Marina Tychopoulos, Florence Bichat, Clothilde Zimmermann, Jean-Pierre Flinois, Monique Diry, Emelie Ahlberg, Marcel Delaforge, Laurent Corcos, Philippe Beaune, Patrick Dansette, François André & Isabelle de Waziers. (2008) Improvement of Cyclophosphamide Activation by CYP2B6 Mutants: From in Silico to ex Vivo. Molecular Pharmacology 73:4, pages 1122-1133.
Crossref
Crossref
Dominique T. Nguyen, Eva Hernandez-Montes, David Vauzour, Axel H. Schönthal, Catherine Rice-Evans, Enrique Cadenas & Jeremy P.E. Spencer. (2006) The intracellular genistein metabolite 5,7,3′,4′-tetrahydroxyisoflavone mediates G2-M cell cycle arrest in cancer cells via modulation of the p38 signaling pathway. Free Radical Biology and Medicine 41:8, pages 1225-1239.
Crossref
Crossref
Partha Roy & David J. Waxman. (2006) Activation of oxazaphosphorines by cytochrome P450: Application to gene-directed enzyme prodrug therapy for cancer. Toxicology in Vitro 20:2, pages 176-186.
Crossref
Crossref
Maria Karlgren, Alvin Gomez, Katarina Stark, Jenny Svärd, Cristina Rodriguez-Antona, Ernst Oliw, Maria Luisa Bernal, Santiago Ramón y Cajal, Inger Johansson & Magnus Ingelman-Sundberg. (2006) Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochemical and Biophysical Research Communications 341:2, pages 451-458.
Crossref
Crossref
Kaveh Asadi-Moghaddam & E. Antonio Chiocca. 2006. Gene Therapy of the Central Nervous System. Gene Therapy of the Central Nervous System
291
301
.
Kaveh Asadi-Moghaddam & Antonio E. Chiocca. 2006. Handbook of Brain Tumor Chemotherapy. Handbook of Brain Tumor Chemotherapy
332
343
.
Sushma Kommareddy, Sandip B. Tiwari & Mansoor M. Amiji. (2016) Long-Circulating Polymeric Nanovectors for Tumor-Selective Gene Delivery. Technology in Cancer Research & Treatment 4:6, pages 615-625.
Crossref
Crossref
Priyanka Parte & David Kupfer. (2005)
OXIDATION OF TAMOXIFEN BY HUMAN FLAVIN-CONTAINING MONOOXYGENASE (FMO) 1 AND FMO3 TO TAMOXIFEN-
N
-OXIDE AND ITS NOVEL REDUCTION BACK TO TAMOXIFEN BY HUMAN CYTOCHROMES P450 AND HEMOGLOBIN
. Drug Metabolism and Disposition 33:10, pages 1446-1452.
Crossref
Crossref
M. Michael & M.M. Doherty. (2005) Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy. Journal of Clinical Oncology 23:1, pages 205-229.
Crossref
Crossref
Tracey L.H. Jason, James Koropatnick & Randal W. Berg. (2004) Toxicology of antisense therapeutics. Toxicology and Applied Pharmacology 201:1, pages 66-83.
Crossref
Crossref
Martijn Rooseboom, Jan N. M. Commandeur & Nico P. E. Vermeulen. (2004) Enzyme-Catalyzed Activation of Anticancer Prodrugs. Pharmacological Reviews 56:1, pages 53-102.
Crossref
Crossref
Sı́lvia Casas, Juha Ollila, Anna Aventı́n, Mauno Vihinen, Jorge Sierra & Sakari Knuutila. (2003) Changes in apoptosis-related pathways in acute myelocytic leukemia. Cancer Genetics and Cytogenetics 146:2, pages 89-101.
Crossref
Crossref
Leaf Huang & Vivian Wai-Yan Lui. 2003. Pharmaceutical Gene Delivery Systems. Pharmaceutical Gene Delivery Systems.
K Binley, Z Askham, L Martin, H Spearman, D Day, S Kingsman & S Naylor. (2003) Hypoxia-mediated tumour targeting. Gene Therapy 10:7, pages 540-549.
Crossref
Crossref
Alex Baldwin, Zeqi Huang, Youssef Jounaidi & David J Waxman. (2003) Identification of novel enzyme–prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Archives of Biochemistry and Biophysics 409:1, pages 197-206.
Crossref
Crossref
Dale F. Kraemer, David Fortin & Edward A. Neuwelt. (2002) Chemotherapeutic dose intensification for treatment of malignant brain tumors: Recent developments and future directions. Current Neurology and Neuroscience Reports 2:3, pages 216-224.
Crossref
Crossref
Manfred Ogris & Ernst Wagner. (2002) Targeting tumors with non-viral gene delivery systems. Drug Discovery Today 7:8, pages 479-485.
Crossref
Crossref
Huiying Li, Jason K. Yano & Thomas L. Poulos. 2002. Cytochrome P450 Part C. Cytochrome P450 Part C
79
93
.
Caroline J. Springer & Ion Niculescu-Duvaz. 2002. Anticancer Drug Development. Anticancer Drug Development
137
155
.
Pamela S. Schwartz & David J. Waxman. (2001) Cyclophosphamide Induces Caspase 9-Dependent Apoptosis in 9L Tumor Cells. Molecular Pharmacology 60:6, pages 1268-1279.
Crossref
Crossref
Frank McCormick. (2001) Cancer gene therapy: fringe or cutting edge?. Nature Reviews Cancer 1:2, pages 130-141.
Crossref
Crossref
D Heine, R Müller & S Brüsselbach. (2001) Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy. Gene Therapy 8:13, pages 1005-1010.
Crossref
Crossref
Zeqi Huang & David J Waxman. (2001) Modulation of cyclophosphamide-based cytochrome P 450 gene therapy using liver P450 inhibitors. Cancer Gene Therapy 8:6, pages 450-458.
Crossref
Crossref
E. Mercadé, M. Cascalló, M. Carrió, J. Calbó, A. Gómez-Treviño, C. Fillat, A.M. Gómez-Foix & A. Mazo. (2001) Treatment based on a combination of the CYP2B1/cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer.. Annals of Oncology 12:3, pages 379-388.
Crossref
Crossref
Thomas Kerbusch, Jan de Kraker, H. Jan Keizer, John W.G. van Putten, Harry J.M. Groen, Rob L.H. Jansen, Jan H.M. Schellens & Jos H. Beijnen. (2001) Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites. Clinical Pharmacokinetics 40:1, pages 41-62.
Crossref
Crossref
Zeqi Huang & David J. Waxman. (1999) High-Performance Liquid Chromatographic–Fluorescent Method to Determine Chloroacetaldehyde, a Neurotoxic Metabolite of the Anticancer Drug Ifosfamide, in Plasma and in Liver Microsomal Incubations. Analytical Biochemistry 273:1, pages 117-125.
Crossref
Crossref